Healthcare / BiotechnologyNasdaqCM
$70.40
-3.46 (-4.68%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-13.9M · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$230M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-26.9%
↓Gross Margin
N/A
•Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+70.9%
FCF CAGR
—
FCF margin
1.4%
FCF / Net income
-0.04x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $19.4M · net income $-6.1M · FCF $275000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $19.4M | $19.4M | $11.5M | $1.6M | $3.9M |
| Net Income | $-6.1M | $-6.1M | $-10.6M | $-27.2M | $-14.9M |
| EBITDA | $-7.4M | $-7.4M | $-11.8M | $-29.0M | $-15.7M |
| EPS | -2.19 | -2.19 | -3.79 | -10.01 | -6.50 |
| Operating Margin | -38.9% | -38.9% | -104.1% | -1885.8% | -418.3% |
| Net Margin | -31.6% | -31.6% | -91.7% | -1752.8% | -384.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | 0.05 | 0.04 | 0.02 |
| Current Ratio | 4.37 | 4.37 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $275000.00 | $275000.00 | $-13.9M | $-17.9M | $-9.7M |
| Returns | |||||
| ROE | -26.9% | -26.9% | -36.7% | -70.5% | -35.4% |
| Valuation | |||||
| P/B | 8.60 | 8.60 | 1.05 | 0.81 | 2.35 |
| Growth & Yield | |||||
| Revenue Growth | 68.0% | 68.0% | 642.5% | -60.0% | — |
| EPS Growth | 42.2% | 42.2% | 62.1% | -54.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+876.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.79 → -2.19
Residual
+876.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.